Efficacy of radiotherapy combined with hepatic arterial infusion chemotherapy, TKI and ICI for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study
Abdominal Radiology · 2024
DOI: 10.1007/s00261-024-04620-1 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Abdominal Radiology, 2024. Verfasst von Hao-Yang Tan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, School of Medicine, The Chongqing University Jiangjin Hospital, Chongqing University, Chongqing, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Portal Vein, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: This retrospective study was conducted to evaluate the effectiveness and safety of a new combination therapy of radiotherapy (RT), hepatic arterial infusion chemotherapy (HAIC), tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI) for hepatocellular carcinoma (HCC) patients involving portal vein tumor thrombus (PVTT). METHODS: A total of 71 HCC patients with PVTT were retrospectively analyzed: 45 patients were treated by 'HAIC + TKI + ICI' therapy and 26 patients by the new combination therapy. The primary outcomes were overall survival (OS), progression-free survival (PFS), and cumulative survival rate. RESULTS: The PFS in the 'New combination therapy' group was longer than that in the 'HAIC + TKI + ICI' group (HR 0.459, 95%CI 0.253-0.832; P = 0.008). Meanwhile, the OS in the 'New combination therapy' group was also longer than that in the 'HAIC + TKI + ICI' group (HR 0.420, 95%CI 0.198-0.894; P = 0.024). Compared with 'HAIC + TKI + ICI' group patients, the 'New combination therapy' group patients had higher 1-year PFS rate and 1-year OS rate (P = 0.029; P = 0.015). There was no significant difference in the incidence of adverse events between the two groups. CONCLUSION: The new combination therapy was an effective and safe non-surgical treatment for HCC patients with PVTT and could be considered a preferred therapy option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, School of Medicine, The Chongqing University Jiangjin Hospital, Chongqing University, Chongqing, China.
- Department of Oncology, School of Medicine, The Chongqing University Jiangjin Hospital, Chongqing University, Chongqing, China.
- Department of Radiology, School of Medicine, The Chongqing University Jiangjin Hospital, Chongqing University, Chongqing, China.
- Department of Hepatobiliary Surgery, School of Medicine, The Chongqing University Jiangjin Hospital, Chongqing University, Chongqing, China. fenghuaguo@126.com.
ORCID-Profile: Hua-Guo Feng
Zitieren
APA
Tan, H. Y., Liu, S. Q., Zheng, J. L., Liu, H. Y., Liu, Y. H., Dai, G. H., & Feng, H. G. (2024). Efficacy of radiotherapy combined with hepatic arterial infusion chemotherapy, TKI and ICI for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study. Abdominal Radiology. https://doi.org/10.1007/s00261-024-04620-1
Vancouver
Tan HY, Liu SQ, Zheng JL, Liu HY, Liu YH, Dai GH, et al. Efficacy of radiotherapy combined with hepatic arterial infusion chemotherapy, TKI and ICI for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study. Abdominal Radiology. 2024. doi:10.1007/s00261-024-04620-1
BibTeX
@article{Tan2024,
author = {Tan, Hao-Yang and Liu, Shuang-Quan and Zheng, Jiu-Ling and Liu, Hong-Ying and Liu, Yan-Han and Dai, Guo-Hua and Feng, Hua-Guo},
title = {Efficacy of radiotherapy combined with hepatic arterial infusion chemotherapy, TKI and ICI for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study},
journal = {Abdominal Radiology},
year = {2024},
doi = {10.1007/s00261-024-04620-1}
}
EUVIMED